This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Conversations in Care: Optimizing Diabetic Retinopathy Treatment With Your Patient

Conversations in Care: Optimizing Diabetic Retinopathy Treatment With Your Patient

Format

Roundtable

Time to Complete

45 minutes

Released

March 4, 2019

Expires

March 4, 2020
Add to Queue


Maximum Credits

0.75 / AMA PRA Category 1 CreditTM
0.75 / COPE CE Credit

Accredited Provider

This educational activity is jointly provided by the American Academy of CME and Spire Learning.

Commercial Supporter

This activity is supported by an educational grant from Genentech, Inc.

Program Description

The incidence of diabetes and diabetic retinopathy (DR) is increasing. Patients experience several barriers to optimal treatment of DR including cost of therapy, insurance coverage, access to care, and ability to attend frequent treatment visits. Working with patients to develop mutually agreeable treatment plans is crucial to overcoming barriers for optimal outcomes. In this 45-minute online video activity, learn about the benefits of shared decision making in the treatment of DR through interactive conversations between retina specialist faculty and their patients.

Intended Audience

Retina specialists, comprehensive ophthalmologists, and optometrists

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Individualize DR therapeutic regimens based on patient factors that may affect their adherence
  • Outline the necessary treatment information to discuss with patients when using a shared decision-making approach for DR management
  • Use educational and communication strategies to individualize the shared decision-making approach with each patient

Conflict Of Interest Disclosure Policy

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

Faculty

Nancy M. Holekamp, MD (Activity Co-Chair)
Professor of Clinical Ophthalmology and Visual Sciences
Washington University School of Medicine
St Louis, MO
Director of Retina Services
Pepose Vision Institute
Chesterfield, MO

Dr. Holekamp discloses the following:
Advisory Board – for marketing purposes: Allergan plc; Genentech, Inc; Novartis Pharmaceuticals; Regeneron Pharmaceuticals, Inc
Advisory Board – for scientific information: BioTime, Inc; Genentech, Inc; Novartis Pharmaceuticals
Consultant – for marketing purposes: Allergan plc; Genentech, Inc; Regeneron Pharmaceuticals, Inc
Consultant – for clinical trial design: BioTime, Inc; Novartis Pharmaceuticals
Shareholder: Katalyst Surgical, LLC
Grant Recipient/Research Support: Alimera Sciences; Allergan plc; Genentech, Inc; Ohr Pharmaceutical, Inc; Ophthotech
Promotional Speaker’s Bureau: Alimera Sciences; Allergan plc; Genentech, Inc; Regeneron Pharmaceuticals, Inc
Intellectual Property/Patents: Katalyst Surgical, LLC

Chirag P. Shah, MD, MPH (Activity Co-Chair)
Assistant Professor of Ophthalmology
Tufts University School of Medicine
Fellowship Co-Director
Tufts New England Medical Center/
Ophthalmic Consultants of Boston Vitreoretinal Surgery Fellowship
Vitreoretinal Specialist
Ophthalmic Consultants of Boston
Boston, MA

Dr. Shah discloses the following:
Advisory Board – for scientific information: Regeneron Pharmaceuticals, Inc
Grant Recipient/Research Support: Alcon; Alimera Sciences; Allergan plc; Fovea Pharmaceuticals; Genentech, Inc; Genzyme; NeoVista, Inc; National Institutes of Health; Novartis Pharmaceuticals; Ophthotech; Regeneron Pharmaceuticals, Inc
Promotional Speaker’s Bureau: Ellex Inc

Lisa S. Schocket, MD
Associate Professor and Vice Chair of Clinical Affairs
Department of Ophthalmology and Visual Sciences
University of Maryland School of Medicine
Chief, Vitreoretinal Disease Section
University of Maryland Eye Associates
Baltimore, MD

Dr. Schocket discloses the following:
Advisory Board – for scientific information: Allergan plc
Employee (Spouse): AstraZeneca

Accredited Provider Disclosures

American Academy of CME, Inc.
John Juchniewicz, MCIS, CHCP: No relevant financial relationships with any commercial interests.

Publishing Staff Disclosures

Spire Learning
Erika Langsfeld, BSMT, PhD, Cara U, PharmD, Molly Vrana, and Lauren Waters: None have any relevant financial relationships with any commercial interests.

Jeanne Prater: Employee (spouse): Novo Nordisk Inc; Shareholder (spouse): Johnson & Johnson (neither relevant to the content of this activity).

Reviewer Disclosure

Alex Yuan, MD, PhD
Cole Eye Institute
Cleveland Clinic
Cleveland, OH

Dr. Yuan has no relevant financial relationships with any commercial interests.

Patient Disclosures

“Henry” and “Sarah” have no relevant financial relationships with any commercial interests to disclose.

Credit

0.75

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc., and Spire Learning. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation Statement

American Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

0.75

Type

COPE CE Credit(s)

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc., and Spire Learning. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation Statement

American Academy of CME, Inc., designates this enduring activity for a maximum of 0.75 COPE credit hours. Optometrists should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of therapies that are not indicated by the FDA, including bevacizumab for the treatment of diabetic retinopathy and diabetic macular edema. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants are encouraged to consult appropriate resources for any product or device mentioned in this activity.

Disclaimer

The opinions expressed in this educational activity are those of the faculty and do not represent those of the Academy or Spire Learning. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

Photo Acknowledgement

Patient images courtesy of Dr Nancy Holekamp and Dr Chirag Shah.

LEVELS OF EVIDENCE

Level I includes evidence obtained from at least one properly conducted, well-designed, randomized controlled trial. It could include meta-analyses of randomized controlled trials.

Level II includes evidence from the following:

  • Well-designed controlled trials without randomization
  • Well-designed cohort or case-control analytic studies, preferably from more than one center
  • Multiple time-series with or without intervention

Level III includes evidence obtained from one of the following:

  • Descriptive studies
  • Case reports
  • Reports of expert committees/organizations (eg, PPP panel consensus with external peer review)
Source: American Academy of Ophthalmology Preferred Practice Patterns® (PPP) Guidelines

Instructions

There is no fee to participate in this activity. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have printed a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For questions about the content of this activity, please contact: CEServices@academycme.org.

For technical questions, please contact: support@archemedx.com.
Add to Queue